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R306465 is a novel hydroxamate-based histone deacetylase (HDAC) inhibitor with broad-spectrum antitumour activity against solid and
haematological malignancies in preclinical models. R306465 was found to be a potent inhibitor of HDAC1 and -8 (class I) in vitro. It
rapidly induced histone 3 (H3) acetylation and strongly upregulated expression of p21
waf1,cip1, a downstream component of HDAC1
signalling, in A2780 ovarian carcinoma cells. R306465 showed class I HDAC isotype selectivity as evidenced by poor inhibition of
HDAC6 (class IIb) confirmed by the absence of downregulation of Hsp90 chaperone c-raf protein expression and tubulin acetylation.
This distinguished it from other HDAC inhibitors currently in clinical development that were either more potent towards HDAC6 (e.g.
vorinostat) or had a broader HDAC inhibition spectrum (e.g. panobinostat). R306465 potently inhibited cell proliferation of all main
solid tumour indications, including ovarian, lung, colon, breast and prostate cancer cell lines, with IC50 values ranging from 30 to 300nM.
Haematological cell lines, including acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphoblastic leukaemia, chronic
myeloid leukaemia, lymphoma and myeloma, were potently inhibited at a similar concentration range. R306465 induced apoptosis and
inhibited angiogenesis in cell-based assays and had potent oral in vivo antitumoral activity in xenograft models. Once-daily oral
administration of R306465 at well-tolerated doses inhibited the growth of A2780 ovarian, H460 lung and HCT116 colon carcinomas in
immunodeficient mice. The high activity of R306465 in cell-based assays and in vivo after oral administration makes R306465 a promising
novel antitumoral agent with potential applicability in a broad spectrum of human malignancies.
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Histone deacetylase (HDAC) inhibitors induce cell-cycle arrest,
terminal differentiation and apoptosis in a broad spectrum of
human tumour cell lines in vitro, and have antiangiogenic and
antitumor activity in human xenograft models (Kim et al, 2001;
Johnstone, 2002; Arts et al, 2003; Dokmanovic and Marks, 2005;
Drummond et al, 2005). Several HDAC inhibitors are in clinical
development where activity has been observed mainly in
haematological malignancies. This has led to the recent approval
of vorinostat (SAHA) for the treatment of cutaneous T-cell
lymphoma (Duvic et al, 2007).
Histone deacetylase inhibitors act on three distinct subclasses of
HDAC enzymes: class I, comprising HDAC1–3 and HDAC8, class
IIa, comprising HDAC4, -5, -7, -9 and class IIb, comprising
HDAC6 and -10. Inhibition of class I HDACs results in the
acetylation of nuclear histone proteins, which affects tertiary
chromatin structure and leads to the altered expression of genes
involved in cell proliferation, apoptosis and differentiation. Class I
HDAC activity is key for uncontrolled proliferation of cancer cells,
since downregulation of HDAC1 and HDAC3 expression results in
increased histone acetylation and inhibition of HeLa cell
proliferation (Glaser et al, 2003). Similarly, knock-out of HDAC1
causes embryonic lethality in mice and severely impaired
proliferation in mouse embryonic stem cells, characterised by an
increase in histone 3 (H3) and histone 4 acetylation and expression
of the cyclin-dependent kinase inhibitors p21
waf1,cip1 and p27.
Upregulation of other class I HDACs (HDAC2 and -3) failed to
compensate for the loss of HDAC1, highlighting its unique
function in regulating cell proliferation (Lagger et al, 2002).
Histone deacetylase 8 is also key to tumour cell growth in vitro, but
instead of impacting on histone acetylation, HDAC8 associates
with cytoskeleton proteins and may play a role in smooth muscle
contractility. Knockdown of HDAC8 by RNA interference inhibits
growth of human lung, colon and cervical cancer cell lines,
highlighting the importance of this HDAC subtype for tumour cell
proliferation. Histone deacetylase 8 also associates with the inv(16)
fusion protein, one of the most frequent chromosomal trans-
locations found in acute myeloid leukaemia (AML), occurring
in over 8% of AML cases (Durst et al, 2003, Waltregny et al,
2005). Recently, HDAC8 was also found to regulate telomerase
activity (Vannini et al, 2004; Lee et al, 2006). In contrast to the
class I HDAC family members, class IIa and IIb HDACs are not
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sdirectly involved in processes that control proliferation and
apoptosis in tumour cells. Downregulation of class IIa members
HDAC4 and HDAC7 in HeLa cells using siRNA technology did
not result in decreased proliferation (Glaser et al, 2003). In
addition, class IIa enzymatic activity is not intrinsic, but derived
from its association with HDAC3 (Fischle et al, 2002). Inhibition
of the class IIb enzyme HDAC6, which is a tubulin and Hsp90
deacetylase, caused a-tubulin hyperacetylation and decreased
cell motility, but did not affect cell-cycle progression (Haggarty
et al, 2003; Zhang et al, 2003). Although inhibition of class II
HDAC enzymes does not result in antiproliferative activity
in vitro, it may potentiate antitumoral effects of other anticancer
agents such as radiation (through HDAC4) (Kao et al, 2003) or
proteasome inhibitors (through HDAC6) (Bali et al, 2005).
The distinct biological roles of HDAC family members strongly
suggest that the selectivity profile of HDAC inhibitors will have
major consequences on their clinical activities. Evidently, to obtain
single-agent antitumoral efficacy with an HDAC inhibitor, potency
towards class I HDAC family members will be essential.
In this paper, we describe the identification of a novel
hydroxamate-based HDAC inhibitor with high selectivity towards
class I HDACs. R306465 showed potent inhibition of HDAC1 and
HDAC8 in vitro and specifically induced histone acetylation in
tumour cells. R306465 did not alter acetylation of the HDAC6
substrate tubulin significantly, in contrast to other HDAC
inhibitors in clinical development that are more potent towards
HDAC6 (e.g. vorinostat) or act as broad-spectrum HDAC
inhibitors (e.g. panobinostat). R306465 demonstrates potent
antiproliferative activity against both solid and haematological
tumour cell lines. Finally, R306465 inhibits angiogenesis and shows
potent antitumour activity after oral administration in human
ovarian, lung and colon tumour xenograft models. The compound
is currently being dosed in cancer patients, to evaluate its potential
applicability in a broad spectrum of human malignancies.
MATERIALS AND METHODS
Compounds
R306465, vorninostat, panobinostat and MS-275 were synthesised
in-house. The different batches of R306465 used in these studies
consistently exceeded a purity of 97% as measured by NMR,
LC-MS and elemental analysis. Trichostatin A was purchased from
Calbiochem, Merck, Darmstadt, Germany. All compounds were
dissolved in dimethylsulphoxide (DMSO) as 5mM stock solutions
and kept at room temperature.
Cell culture
All cell lines were cultured at 371C in a humidified incubator with 5%
CO2. Media and supplements were obtained from Life Technologies,
(Merelbeke, Belgium). All cell lines were obtained from ATCC
(American Type Culture Collection, Manassas, VA, USA) unless
stated otherwise and cultured according to instructions. The human
K562A7 leukaemia cell line was a kind gift by Dr H Heyligen
(Dr Willems Instituut, Diepenbeek, Belgium) and was kept as a
suspension culture in RPMI-1640 medium supplemented with 2mM
L-glutamine, 50mgml
 1 gentamicin and 5% FCS. Primary human
HMEC mammary epithelial cells (Clonetics, North Brunswick, New
Jersey, USA) were obtained from BioWhittaker (Verviers, Belgium)
and cultured in the mammary epithelial cell growth medium
supplemented with growth factors and antibiotics as described by
the supplier. Human umbilical cord endothelial cells (HUVECs)
(Cascade Biologics C-015-10C, Invitrogen, Merelbeke, Belgium) were
grown in M-200 media supplemented with Low Serum Growth
Supplement (Cascade Biologics M-200-500 and S-003-10, Invitrogen,
Merelbeke, Belgium).
Cell-proliferation assays and combination studies
The effect of HDAC inhibitors on cell proliferation was measured
using an MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide)-based assay (Serva, Heidelberg, Germany).
Cells were seeded in Falcon or NUNC 96-well culture plates (Life
Technologies, Merelbeke, Belgium) in 100ml culture medium and
allowed to adhere to plastic for 18–48h. Test compounds
were dissolved in DMSO and further dilutions were made in
culture medium, with final concentrations of DMSO never
exceeding 0.1% (vv
 1), and incubated for 4 days. Proliferation
of NSCLC was assessed using Alamar Blue-based assay. Cells
were seeded in COSTAR 384-well culture plates in 45ml culture
medium and allowed to adhere to plastic for 24h. Alamar blue was
added after 72h, with the exception of HCC-15, HCC-44, NCI-
H2122 and NCI-H460, where Alamar blue was added after 90h and
OD values were measured at 4 days following compound exposure.
Data are presented as mean±s.d. of three independent experi-
ments. The IC50 values were calculated by non-linear regression
analysis using SigmaPlot 4.01 software. A BrdU incorporation
assay was used to measure HUVEC proliferation. Human umbilical
cord endothelial cells were seeded at 10
4cells per well in a 96-well
plate in F12K 0.2% FCS (Gibco/BRL 21127-022, Invitrogen,
Merelbeke, Belgium) and allowed to adhere for 20h. Subsequently,
proliferation was induced by adding low-serum growth supple-
ment (Cascade Biologics Cat no. S-003-10) and compounds were
added at the indicated concentrations. The next day, BrdU
incorporation was evaluated over a 24-h period using the BrdU
kit from Roche according to the manufacturers description (Roche
1 647 229, Vilvoorde, Belgium). For proliferation of haematological
cell lines and the combination studies of R306465 and Bortezomib
(PS-341, Velcade), tumour cells were plated in 96-well flat-bottom
microtitration plates and incubated at 371C for 24h before
treatment in 180ml of drug-free complete cell culture medium.
Typically, five concentrations (in 1/3 dilution steps; so as not to
exceed 30–40% inhibition of cell proliferation as single agent) of
R306465 were combined with five concentrations (in 1/3 dilution
steps; so as not to exceed 30–40% inhibition of cell proliferation as
single agent) of Bortezomib (PS-341, Velcade
s). Control cells were
treated with the combined respective vehicle. Cells were incubated
for 72h in the presence of combined test substances at 371C under
5% CO2. At the end of treatments, the cytotoxic activity was
evaluated by an MTS assay. At least three independent experiments
were performed, each result being issued from quadruplicate
determination. Dilutions of each test substance as well as
distribution to plates containing cells were performed using a
Sciclone ALH 3000 liquid handling system. The compound
interactions were calculated by multiple drug effect analysis and
were performed by the median equation principle according to the
methodology described by Chou and Talalayb (1984). The
combination index (CI) was calculated by the Chou et al equation
(Chou and Talalayb, 1984; Chou et al, 1994), which takes into
account both the potency and the shape of the dose–effect curve.
Each CI was calculated with CalcuSyn software (Biosoft, UK) from
the mean affected fraction at each drug ratio concentration. For
each independent experiment, the median CI was calculated from
all relevant CI values corresponding to each drug combination
tested.
Cell-cycle analysis
Human A2780 ovarian carcinoma cells were seeded at 2 10
6cells
per 75-cm
2 flask and, after 24h, incubated with the indicated
concentration of test compound. To analyse cell-cycle distribution,
sub-confluent cells were collected, centrifuged and washed with
PBS. The cell pellets were re-suspended in citrate buffer and nuclei
were stained with propidium iodide (Sigma-Aldrich, Bornem,
Belgium) as described previously (Vindelov et al, 1983). Analysis
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swas carried out using a BD-LSR flow cytometer (BD Biosciences,
Erembodegem, Belgium) equipped with an argon laser (488nm
excitation). Cell-cycle profiles were analysed using WinList 3D
version 4.0 and areas under the curve were calculated using ModFit
LT version 3.1 (Verity Software House Inc.).
Annexin V staining
Human A2780 ovarian carcinoma cells were seeded at 2 10
6cells
per 75-cm
2 flask and, after 24h, incubated with the indicated
concentration of test compound for 48h. The cells were
subsequently collected, centrifuged and washed with PBS. The cell
pellets were stained with Annexin-V-FITC antibody and propi-
dium iodide with a kit from PharMingen, BD Biosciences,
Erembodegem, Belgium (cat 66121E).
Rat aortic ring assay
Angiogenesis inhibitory activity was measured using the in vitro
rat aortic ring assay (Nicosia and Ottinetti, 1990). Briefly, thoracic
aorta were freshly isolated from 1- to 2-month-old Sprague–
Dawley rats and 1-mm-long sections (aortic rings) were embedded
in fibrin gel clots in six-well plates. Serum-free MCDB-131 media
were added to the wells and the cultures were incubated at 371Ci n
5% CO2. Test compounds were added at the indicated concentra-
tions at day 0 and again together with fresh media on day 2 and
day 5 of culture. The ability of experimental compounds to inhibit
microvessel outgrowth was compared directly with vehicle-treated
control rings. Quantification of microvessel growth following 8
days in culture was performed using an automated image analysis
system consisting of a light microscope equipped with a CCD
camera and an automated, custom-designed image analysis
program (Nissanov et al, 1995). Microvessel area, expressed as
pixels
2, was determined for each aortic ring and the per cent
inhibition of microvessel area compared to control rings was
calculated using the mean values for each treatment group.
Statistical differences between experimental groups (five indepen-
dent rings) were analysed by ANOVA and Dunnett’s t-test, with a
P-value of o0.05 or less considered statistically significant.
Histone deacetylase activity assays
For assessing HDAC1 activity, A2780 ovarian tumour cells were
trypsinised and resuspended in RIPA buffer (50mM Tris–HCl, pH
7.4, 1% NP40, 0.25% sodium deoxycholate, 150mM NaCl, 1mM
EDTA, 1mM Na3VO4 and EDTA-free protease inhibitor cocktail)
and sonicated for 20s. After centrifugation, the cleared extract was
used for immunoprecipitation of HDAC1. The protein extract
(100mg) was precleared for 1h at 41C with normal mouse IgG
serum (Santa Cruz sc-2025, Heidelberg, Germany). Subsequently,
the lysate was rotated at 41C for 4h with anti-HDAC1 protein A
agarose beads (Upstate 06720, Blognost, Heule, Belgium). Histone
deacetylase 1 activity was measured by incubating the HeLa
nuclear extracts (3mg, Biomol, Exeter, UK) or immunoprecipitated
HDAC1 complexes with an [
3H]acetyl-labelled fragment of histone
H4 peptide (B50000c.p.m.) [biotin-(6-aminohexanoic)Gly-Ala-
(acetyl[
3H])Lys-Arg-His-Arg-Lys-Val-NH2] (Amersham Pharma-
cia Biotech, Piscataway, NJ, USA) in a total volume of 50ml enzyme
assay buffer (25mM HEPES (pH 7.4), 1 M sucrose, 0.1mgml
 1 BSA
and 0.01% (vv
 1) Triton X-100). Incubation was performed for
45min at 371C (immunoprecipitates) or 30min at room tempera-
ture (HeLa nuclear extract). Before addition of substrate, HDAC
inhibitors were added at increasing concentrations and preincu-
bated for 10min at room temperature. After incubation, the
reaction was quenched with 35ml stop buffer (1 M HCl and 0.4 M
acetic acid). Released [
3H]acetic acid was extracted with 800ml
ethyl acetate and quantified by scintillation counting. Equal
amounts of HDAC1 were immunoprecipitated as indicated by
western blot analysis. Histone deacetylase 1 activity results
are presented as mean±s.d. of three independent experiments
on a single lysate. For inhibition of human recombinant HDAC8,
the HDAC8 Colorimetric/Fluorimetric Activity Assay/Drug Dis-
covery Kit (cat no. AK-508; Biomol) was used. Finally, we
measured the activities of different HDAC isotypes present in
partially purified extract from rat liver using the fluorescent HDAC
substrates MAL (unselective), B61 (selective for HDAC1, and to
some extent also converted by HDAC3) and B12 (selective for
HDAC6). Assays were performed in duplicate and the s.e. of the
IC50 was calculated using Graphpad Prism (Graphpad Software)
(Heltweg et al, 2004).
Western blot analysis
Human A2780 ovarian carcinoma cells were incubated with the
indicated concentrations of HDAC inhibitors. Total cell lysates
were prepared and analysed by SDS–PAGE. Levels of acetylated
H3 and H4 histones, total H3 protein and p21
waf1,cip1 protein were
detected using rabbit polyclonal and mouse monoclonal anti-
bodies, followed by ECL detection (Upstate Biotechnology 06-599
and 06-866, Abcam ab1791, Cambridge, UK and Transduction
Laboratories C24420, BD Biosciences, Erembodegem, Belgium).
Levels of total and acetylated tubulin were detected using clone
DM1A (Sigma T9026) and clone 6-11B-1 (Sigma T6793). Anti-
bodies for Hsp70 and c-raf were obtained from Transduction
(610152) and Stressgen, Michigan, USA (SPA-810), respectively. To
control for equal loading, blots were stripped and re-probed with
mouse monoclonal antiactin IgM (Ab-1, Oncogene Research
products, Merck, Darmstadt, Germany). As secondary antibodies,
HRP-labelled anti-mouse (sc-2005, Santa Cruz Biotechnology) and
anti-rabbit (65-6120, Zymed, Invitrogen, Merelbeke, Belgium)
and fluorochrome-labelled anti-mouse (610-131-121, Rockland,
Gilbertsville, USA) and anti-rabbit (A21076, Molecular Probes,
Invitrogen, Merelbeke, Belgium) were used. Protein–antibody
complexes were then visualised by chemiluminescence (Pierce
Chemical Co., Perbioscience, Erembodegem, Belgium) or fluores-
cence (Odyssey) according to manufacturer’s instructions.
p21
waf1,cip1 Promoter activity in vivo
To generate an HDAC inhibitor-responsive p21
waf1,cip1 promoter
construct, the –1300 to þ88 region of the p21
waf1,cip1 promoter
was cloned into pGL3-basic-ZsGreen and stably transfected into
A2780 ovarian carcinoma cells (Belien et al, 2006). For in vivo
analysis of p21
waf1,cip1 promoter activity, A2780-p21
waf1,cip1Zs-
Green cells were injected s.c. (10
7cells per 200ml) into the inguinal
region of Nude mice and caliper-measurable tumours were
obtained after 12 days. From day 12 onwards, mice were treated
orally (p.o.) once with solvent or the indicated dose of R306465 (10
animals per group). Tumours were collected using transcardial
perfusion fixation with 4% paraformaldehyde. Cryosections of
10-mm thickness were mounted on glass slides and air-dried for
30min at room temperature. Bodipy 558/568-phalloidin staining
was performed on whole mounts to visualise actin (background
cell staining). ZsGreen fluorescence was evaluated with an
Axioplan 2 (Zeiss, Germany) equipped with Epiplan-Neofluar
objectives and an Axiocam camera. CD-31 (CY3) immunofluor-
escent labelling was performed on whole mounts to visualise the
endothelium of blood vessels. Mounted samples were observed
with the LSM510 laser scanning microscope.
Immunohistochemistry
For immunofluorescent staining of AcH3, cryosections of A2780
ovarian carcinoma were fixed for 2min in 4% neutral buffered
formalin and subsequently for 10min in ethanol (100%). After
blocking with goat immunoglobulin (Jackson Immunoresearch
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sLaboratories, Suffolk, UK) for 60min, the sections were incubated
with anti-AcH3 (Upstate, 1/5000) for 2h and with goat anti-rabbit
CY3-conjugated secondary antibody (1/500 Jackson Immuno-
research Laboratories) for 2h. For negative controls, primary
antibody was omitted. Nuclei were counterstained using Hoechst
(1/2000) for 5min and the cryosections were mounted in glycerin-
gelatin. Images were taken using the Zeiss Axioplan 2 & Axiocam,
and processed using Photoshop 7.0 and Image Tool Processing Kit.
Representative images of each group (n¼3) are shown. For
TUNEL staining, cells were fixed with 4% paraformaldehyde for
5min and then incubated for 1h at 371C in a solution containing
25mM Tris, 200mM sodium cacodylate, 1.25mgml
 1 BSA, 1.25mM
CoCl2,1 0m M dATP (Sigma Chemical Company), 2.5mM fluorescein-
dUTP (Amersham Pharmacia Biotech AB) and 50Uml
 1 TdT
(Roche, Vilvoorde, Belgium). Incorporated Fluorescein-dUTP was
detected with a sheep antifluorescein peroxidase-conjugated
antiserum (Boehringer Mannheim, 1/600, Roche, Vivoorde,
Belgium). The peroxidase conjugate was visualised using amino
ethylcarbazol.
In vivo antitumoral studies
R306465 was formulated at 2mgml
 1 in 20% hydroxypropyl-b-
cyclodextrin (final pH 8.7) as an injectable solution. All mice used
in the in vivo studies were athymic male NMRI nu/nu mice
purchased from Janvier (France) and were treated according to the
ethical guidelines prescribed by UKCCCR. A2780 ovarian, HCT116
colon and H460 lung carcinoma cells were injected s.c. (10
7cells
per 200ml) into the inguinal region of Nude mice. From day 4
onwards, mice were dosed orally daily during 28 days (QDx28,
p.o.) with the indicated dose of R306465 (10 animals per group,
0.5ml per mouse). Tumour size was determined using caliper
measurement and tumour volume was determined by using the
formula: TV¼(a
2 b)/2 (in which a represents the width and b
the length).
RESULTS
Identification of R306465 as a potent Histone deacetylase
inhibitor
R306465 (Figure 1) was identified as potent novel hydroxamate-
based inhibitor of histone deacetylase 1 (HDAC1) inhibiting
immunoprecipitated HDAC1 complexes in vitro with an IC50 value
of 3.3nM and A2780 ovarian tumour cell proliferation with an
IC50 of 39nM (Table 1). A comparison of several other HDAC
inhibitors currently in clinical development confirmed that
panobinostat (LBH589) is also a highly potent inhibitor of both
HDAC1 activity and tumour cell proliferation in vitro (Bali et al,
2005), while vorinostat (SAHA) showed lower potency towards
both HDAC1 and tumour cell proliferation, which is in agreement
with previous publications (Butler et al, 2000). The benzamide MS-
275 did not inhibit HDAC1 enzyme activity up to 1mM, and showed
low antiproliferative potency. R306465 inhibited the class I HDAC8
at least 10 times more potently than vorinostat and panobinostat
(Table 1). We have not studied cellular activity towards HDAC8
since its natural substrates have not been identified until recently,
when Lee et al (2006) demonstrated that HDAC8 stabilises ‘human
ever-shorter telomeres 1B’ and thereby sustains telomerase
activity. Activity towards HDAC1–3 and HDAC8 has been
demonstrated to be essential for tumour cell proliferation (Glaser
et al, 2003).
To study HDAC subtype selectivity of R306465 in further detail,
we compared deacetylation of the HDAC1/HDAC3 substrate, B61,
and the HDAC6-specific substrate, B12 (Heltweg et al, 2004) in a
rat liver HDAC preparation. R306465 preferentially inhibited
deacetylation of B61, while vorinostat was 9-fold more potent in
inhibiting the deacetylation of the HDAC6-specific substrate
(Table 1). Panobinostat demonstrated equipotent activity towards
both substrates.
Since R306465 differed from other HDAC inhibitors in showing
high class I selectivity in vitro, we subsequently investigated HDAC
subtype selectivity in cells. We evaluated the acetylation status in
A2780 ovarian carcinoma cells of H3, which is acetylated through
class I HDACs (Glaser et al, 2003), and tubulin, which is acetylated
by the class II family member HDAC6 (Matsuyama et al, 2002;
Zhang et al, 2003). Inhibition of HDAC6 also induces Hsp90
acetylation, resulting in Hsp70 induction and degradation of
Hsp90-associated pro-survival and pro-proliferative client proteins
such as c-raf (Bali et al, 2005).
R306465 induced H3 acetylation and p21
waf1, cip1 induction
at concentrations as low as 100nM (Figure 2). Tubulin
acetylation and Hsp70 levels, on the other hand, increased
only at concentrations as high as 1mM, indicating a 10-fold
higher cellular potency for HDAC1 vs HDAC6, reflecting class I
selectivity observed in vitro (Table 1). Vorinostat on the other
hand, induced H3 acetylation only at 1–3mM, while tubulin
acetylation and Hsp70 induction were already evident at 100nM,
indicating a 10-fold higher potency for HDAC6 for this agent.
The other hydroxamic acid-based HDAC inhibitors, panobinostat
and TSA, inhibited HDAC1/HDAC6 at similar concentrations,
since both substrates were acetylated at 100 and 300nM,
respectively. The benzamide MS-275 induced H3 acetylation
at 3mM, but did not affect tubulin acetylation or Hsp70 levels
N
N O
N
H
O H
N N S
O
O
Figure 1 Chemical structure of R306465.
Table 1 Inhibition of HDAC isozymes and tumour cell proliferation (IC50,n M)
Liver extract
Enzyme substrate HDAC1-IP Ac-H4 HDAC8 MALunselective B61HDAC1 B12HDAC6 A2780 proliferation
R306465 3.31±0.78 23±17 886±85 51±8 1541±290 39±17
Vorinostat 73±26 370±314 132±7 1032±201 150±9 1157±578
Panobinostat 0.23±0.06 283±29 75±44 7 ±58 9 ±12 4.6±1.8
MS-275 41000 410000 Inactive Inactive Inactive 376±169
TSA 1.67±0.22 135±51 12±1.2 13.3±1.4 20.7±2.6 23±8
Abbreviations: HDAC¼histone deacetylase; TSA¼trichostatin A Inhibition of HDAC activity with R306465 (JNJ-16241199), panobinostat, vorinostat and MS-275 was assessed
using a number of different assays: for HDAC1 activity assays, HDAC1 was immunoprecipitated from A2780 cell lysates as indicated in the Methods section and incubated with a
concentration range of the indicated HDAC inhibitor. Recombinant HDAC8 activity was measured as indicated in the Methods section. Finally, HDAC isotype activity was
measured in rat liver extract using an HDAC1-selective (B61), -unselective (MAL) and an HDAC6-selective (B12) substrate (Heltweg et al, 2004). A2780 tumour cell
proliferation was measured using a standard MTT colorimetric assay as indicated in the Methods section. Results are expressed as average IC50 values (nM)±s.d. for three
independent experiments.
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sat this concentration. These data confirm that R306465 is a
specific inhibitor of HDAC1/3 in A2780 tumour cells, which
is in contrast to other HDAC inhibitors in clinical
development that are more potent towards HDAC6 (e.g.
vorinostat) or have a broader spectrum of activity (e.g.
panobinostat).
Ac-Tub
Tub
AcH3
H3
p21waf1,cip1
Actin
Lamin B1
Hsp70
c-raf
Concentration (M)
Vorinostat TSA Panobinostat MS-275 R306465
0.03 0.1 0.3 1 0.1 00 . 3 13 0 0.03 0.1 0.3 1 0 0 .10 .3 13 0 0. 1 0.3 13 0
H
D
A
C
1
–
3
H
D
A
C
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Figure 2 Substrate selectivity of R306465. Human A2780 ovarian carcinoma cells were incubated with the indicated concentrations of R306465,
vorinostat, panobinostat, MS-275 or Trichostatin A (TSA) for 24h. Total cell lysates were prepared and analysed by SDS–PAGE. Levels of acetylated H3
and tubulin, and of total levels of H3 and tubulin and of p21
waf1, cip1 and Hsp70 and c-raf protein, were detected using rabbit polyclonal and mouse
monoclonal antibodies, followed by ECL detection as indicated in the Methods section. To control for equal loading, blots were stripped and re-probed with
antibodies against actin and the nuclear protein Lamin B1. A representative experiment out of three is shown.
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Figure 3 Antiproliferative activity of R306465. Human tumour cell lines were seeded at low cell density and after 24h cells were incubated with R306465
at 3 10
 9,1 0
 8,3 10
 7,1 0
 6,3 10
 6 and 10
 5 M. The number of viable cells after a 4-day incubation period was assessed using a standard MTT
colorimetric assay or Alamar Blue assay as indicated in the Methods section. Values represent mean±s.d. of three independent experiments. For
haematological tumour cell lines, IC40 values (concentrations leading to 40% inhibition of cell proliferation) were determined for technical reasons: (ALL)
acute lymphoblastic leukaemia; (AML) acute myeloid leukaemia; (CLL) chronic lymphoblastic leukaemia – EHEB (chronic B cell leukaemia); and (CML)
chronic myeloid leukaemia.
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against solid and haematological cancer cell lines
Histone deacetylase 1–3 and HDAC8 have been demonstrated to
be key for tumour cell proliferation (Glaser et al, 2003). We
therefore investigated the antiproliferative effects of R306465 in a
broad panel of human tumour cell lines from both solid and
haematological origin. As indicated in Figure 3, R306465 inhibited
cell proliferation in all lung, breast, colon, prostate and ovarian
tumour cell lines tested, with IC50 values ranging from 38 to
338nM. This antiproliferative effect was not dependent on p53
genotypic status, nor ras mutational status in colon and lung
tumour cells (data not shown). Similarly, R306465 inhibited
proliferation with comparable potency in acute lymphoblastic
leukaemia (ALL), AML, chronic lymphoblastic leukaemia (CLL),
chronic myeloid leukaemia (CML), lymphoma and myeloma
tumour cells (IC50 values¼15–486nM). Primary human mam-
mary epithelial cell (HMEC) proliferation was inhibited at similar
concentrations as tumour cells (IC50¼32±9.7nM) but quiescent,
non-proliferative HMEC cells were insensitive to the effects of
R306465 (IC50¼7815±435nM, data not shown).
Histone deacetylase 6 has been reported to potentiate the effects
of proteasome inhibitors (Bali et al, 2005). The observation that
R306465 mainly affects HDAC1, but not HDAC6 activity,
prompted us to investigate whether R306465 could work
synergistically with Bortezomib (Velcade). As indicated by the CI
in Table 2, R306465 and Bortezomib show potent additivity and
synergy in a large panel of haematological tumour cell lines,
including ALL, AML, CML, lymphoma and myeloma. These data
suggest that activity towards HDAC6 may not be necessary for
synergy with Bortezomib.
R306465 induces apoptosis and inhibits angiogenesis
To investigate whether the antiproliferative effect of R306465 in
A2780 ovarian tumour cells was due to induction of cell-cycle
arrest or cell death, FACS analysis was performed. As shown in
Figure 4, after 24h incubation, a concentration-dependent
decrease in S phase (DNA synthesis) was observed at 300nM, with
a parallel increase in G1 phase. However, at higher concentrations
(1mM), an increase in the sub-G1 fraction of cells was observed.
After 48h, an increase in sub-G1 phase was observed at all active
concentrations, starting from 100nM, suggesting that the anti-
proliferative effect of R306465 is linked to A2780 cell death.
R306465 treatment caused a significant increase in the percentage
of cells positive for Annexin V in a concentration-dependent
manner indicative of apoptosis. An increase in the number of
necrotic cells was also observed, which likely represents apoptotic
cells in later stages of cell death. Induction of apoptosis was further
confirmed by an increase in cells showing DNA fragmentation as
assessed by TUNEL staining (inset, Figure 5A). In subsequent
experiments, HDAC inhibitors also induced substantial apoptosis
in HCT116 and HT-29 colon tumour cells, DU145 prostate cancer
cells and H1299 large cell carcinoma, pointing at apoptosis as a
major denominator of response in vitro (data not shown). R306465
also inhibited angiogenesis as demonstrated by a decrease of
microvessel growth in the rat aortic ring assay (Figure 5B). Total
microvessel area was significantly inhibited by 67±7% (mean±
s.e.m.) at 300nM compared to controls. The antiangiogenic effect
of R306465 is in agreement with its antiproliferative potency for
primary human endothelial cells. R306465 inhibited the growth of
HUVECs with an IC50 of 186±23nM.
R306465 induces H3 acetylation and p21
waf1,cip1 promoter
activity in A2780 ovarian tumour tissue in vivo
The antiproliferative and cytotoxic effect of HDAC1 inhibition is
linked to increased histone acetylation status. To assess whether
R306465 increases H3 acetylation in vivo, immunodeficient mice
bearing human A2780 ovarian xenografts were treated with R306465
orally once daily at 40mpk (mgkg
 1), and tumours were harvested
4h after dosing at different days. An increase in acetylation was
observed at the edge of the tumour tissue 4h after the first
treatment, while on day 2, a maximal and homogeneous increase in
H3 acetylation was observed throughout the tumour tissue
(Figure 6). To visualise subsequent activation of downstream
signalling pathways in vivo, we used a fluorescence-based gene
expression xenograft model in which green fluorescent protein
expression is driven by the promoter of the cyclin-dependent kinase
inhibitor p21
waf1,cip1 (Belien et al,2 0 0 6 ) .T r e a t m e n to ft u m o u r -
bearing mice with HDAC1 inhibitors results in de-repression of the
p21
waf1, cip1 gene and induction of fluorescence in vivo.A ss h o w ni n
Figure 6A, control tumour sections displayed only a few fluorescent
cells. On the other hand, tumour sections treated only once with
R306465 at 40mpk (p.o.), contained a large number of fluorescing
cells 24h after dosing, indicative of p21
waf1,cip1 promoter activation
in the ovarian tumour tissue. ZsGreen fluorescence was not uniform
throughout the tissue; areas of high fluorescence containing a few to
hundreds of cells were surrounded by areas with weaker intensity.
The clusters containing cells that responded to the treatment were
distributed evenly throughout the peripheral and central parts of the
tumour and did not colocalise with tumour vasculature structures
(Figure 6A and B).
R306465 inhibits tumour growth in vivo after oral
administration
R306465 administered continuously for 28 days (once daily, up to
40mpk p.o.) to immunodeficient mice was well-tolerated. As
illustrated in Figure 7, a potent time- and dose-dependent
Table 2 Combination of R306465 and Bortezomib in haematological
cell lines in vitro
Cell line Origin
CI
(mean±s.d.)
Combination
analysis
CCRF-CEM ALL 0.93±0.11 Additive
Jurkat ALL 1.32±0.27 Antagonism
KG-1 ALL 0.90±0.20 Additive
MOLT-4 ALL 0.81±0.06 Synergy
SUP-B15 AML 0.75±0.03 Synergy
HL-60 AML 1.01±0.11 Additive
OCI-AML2 AML 0.70±0.17 Synergy
THP-1 AML 0.87±0.06 Synergy
EHEB CLL 1.07±0.06 Additive
BV-173 CML 0.83±0.06 Synergy
K-562 CML 0.88±0.25 Synergy
KCL-22 CML 0.90±0.20 Additive
LAMA-84 Lymphoma 1.08±0.09 Additive
U-937 Lymphoma 0.65±0.22 Synergy
Daudi Lymphoma 0.95±0.15 Additive
Namalwa Lymphoma 0.76±0.05 Synergy
Raji Lymphoma 0.55±0.02 Synergy
Ramos Lymphoma 1.31±0.14 Antagonism
ARH-77 Myeloma 0.91±0.09 Additive
RPMI 8226 Myeloma 0.84±0.19 Synergy
Abbreviations: ALL¼acute lymphoblastic leukaemia; AML¼acute myeloid leukae-
mia; CLL¼chronic lymphoblastic leukaemia; CML¼chronic myeloid leukaemia.
Tumour cells were incubated with five concentrations of R306465, combined with
five concentrations of Bortezomib (PS-341, Velcade
s) for 72h as described in the
Methods section. The combination index (CI) was calculated by the Chou et al
equation (Chou et al, 1994). For each independent experiment, the median CI was
calculated from all relevant CI values corresponding to each drug combination tested.
Results are expressed as average IC50 values (nM)±s.d. for three independent
experiments.
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sinhibition of tumour growth was observed in the A2780 ovarian
xenograft model (panel A). Maximal decrease in final tumour
volume was found to be 76–87%, which was obtained both at 20
and 40mpk doses. Potent and dose-dependent antitumoral efficacy
for R306465 after oral administration was also observed in lung
(H460) and colon (HCT116) xenograft models (Figure 7). The
activity of R306465 in a panel of different human tumour xenograft
models suggests that this agent may have applicability against a
broad spectrum of human malignancies.
DISCUSSION
In this paper, we describe a novel hydroxamate-based HDAC
inhibitor with potent antiproliferative activity in a broad spectrum
of cancer cell lines and antitumoral activity after oral administra-
tion in ovarian, lung and colon xenograft models. In agreement
with the potent inhibition of class I HDAC enzymes, R306465
showed broad-spectrum antiproliferative activity against all main
solid tumour indications in vitro, including lung, breast, colon,
prostate and ovarian cancer cell lines. Similarly, growth of
haematological cell lines ALL, AML, CLL, CML, lymphoma and
myeloma was potently inhibited. R306465 differs from other
hydroxamate-based inhibitors currently in clinical development in
that it has preferential activity towards class I HDACs compared to
HDAC6. So far, for the HDAC inhibitors in clinical development,
HDAC1 selectivity has been reported only for non-hydroxamic
acid-based HDAC inhibitors, such as the benzamide MS-275
(Blagosklonny et al, 2002; Hu et al, 2003; Glaser et al, 2004). In our
hands, however, MS-275 did not inhibit the activity of HDAC1
complexes precipitated from tumour cells and induced cellular H3
acetylation only at very high concentrations. HDAC1 inhibition by
MS-275 in vitro has usually been demonstrated using recombinant
HDAC1 enzymes (Hu et al, 2003). Assessing HDAC inhibitor
selectivity in vitro must be approached with caution since active
enzymes consist of a multiprotein complex containing other
HDACs and cofactors. In agreement with our data, Park et al
(2004) and Kraker et al (2003) also observed modest activity of
MS-275 while using immunoprecipitated HDAC1 multiprotein
complexes from cancer cells. It therefore appears likely that
MS-275 inhibits HDAC1 in its endogenously biologically active
multiprotein complex less potently than as a recombinant protein.
In addition to HDAC1, R306465 also showed high potency in vitro
towards HDAC8. Inhibition of HDAC8 is desirable, since
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Figure 4 R306465 affects cell-cycle distribution. Human A2780 ovarian carcinoma cells were incubated with the indicated concentrations of R306465 for
24 or 48h. DNA content of nuclei was evaluated using propidium iodide staining followed by FACS analysis, and the number of cells in sub-G1,G 1, S and
G2M phase was calculated as a percentage of control. Results are expressed as % of total cells and a representative experiment out of three is shown.
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sknockdown of HDAC8 by RNA interference inhibits growth of
human lung, colon and cervical cancer cell lines, highlighting the
importance of this HDAC subtype in tumour cell proliferation.
Histone deacetylase 8 is also responsible for the transcriptional
repression by the inv(16) fusion protein, one of the most frequent
chromosomal translocations found in AML, occurring in over 8%
of AML cases. Histone deacetylase inhibitors in clinical develop-
ment were found to be either equipotent against HDAC6 and class
I HDACs (panobinostat) or show preferential activity towards
HDAC6 (vorinostat). Selectivity of vorinostat towards HADC6 has
not been observed previously, possibly because most previous
studies were performed with a generic ‘Fluor-de-Lys’ HDAC
substrate (Koeller et al, 2003; Glaser et al, 2004). When using
HDAC isotype-specific substrates, R306465 showed poor inhibi-
tion of deacetylation of an HDAC6-specific synthetic substrate,
which was confirmed while analysing HDAC1–3 (H3) and HDAC6
substrates (Tubulin, Hsp90) in A2780 ovarian carcinoma cells. The
modest effect of R306465 on tubulin deacetylation was surprising
because this has previously been shown only for hydroxamic acid-
based HDAC inhibitors with a very large capping group (Glaser
et al, 2004), which is not the case for R306465. A unique aspect of
HDAC6 is the presence of two catalytic domains: a C-terminal
TDAC pocket that possesses a-tubulin deacetylase activity
(Hubbert et al, 2002) and an N-terminal catalytic domain that is
likely responsible for Hsp90 deacetylation. A specific inhibitor of
the TDAC catalytic domain only partially inhibited total HDAC6
catalytic activity and poorly induced Hsp90 acetylation (Haggarty
et al, 2003; Bali et al, 2005). All HDAC inhibitors examined in this
study (R306465, vorinostat, panobinostat and TSA) showed
comparable potency towards both catalytic domains of cellular
HDAC6, since tubulin acetylation and inhibition of Hsp90 function
were observed at similar concentrations in A2780 ovarian
carcinoma cells. Since the activity of HDAC6 is not essential for
tumour growth, HDAC6 inhibition likely does not contribute to
single agent antitumoral activity of HDAC inhibitors. The clinical
implication of the preferential activity of R306465 towards HDAC1
compared to HDAC6, however, is difficult to predict. Histone
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Figure 5 R306465 induces apoptosis in human A2780 ovarian carcinoma
cells and inhibits angiogenesis. (A) A2780 ovarian carcinoma cells were
incubated with the indicated concentrations of R306465 for 48h. Cells were
stained with Annexin V (Pharmingen) and propidium iodide, and analysed by
FACS. Apoptotic cells show Annexin V binding on the plasma membrane, but
cells are intact and therefore do not stain for propidium iodide. Membrane-
damaged cells were defined as both Annexin V- and propidium iodide-
positive. Shown are mean values±variation for two independent experi-
ments. Inset: cells incubated with R306465 (100nM) were stained for DNA
breaks using TUNEL dUTP labelling followed by peroxidase staining. Green
asterisks represent mitotic cells, while red arrows point at specific DNA
fragmentation. (B) Rat Aortic Ring Assays were performed as described in the
Methods section. Aortic rings were incubated with either solvent or with the
indicated concentrations of R306465 for 8 days and the average microvessel
area for five independent rings was quantified.
Solvent R306465
Day 1 Day 2
Control
Day 4
4
Day 10
R306465
2
Figure 6 R306465 induces histone acetylation and activates the p21
waf1,cip1 promoter in vivo. Nude mice were injected s.c. with A2780 ovarian carcinoma
cells and subsequently treated p.o. once daily with vehicle (20% HP-b-CD, control) or R306465 at 40mpk (R306465). (A) Tumours were harvested 4h
after the last dose. Nuclei are stained with Hoechst, while (CY3) immunofluorescent labelling was performed to visualise acetylated H3. Representative
sections from four independent mice are shown. (B) and (C) Tumours were collected after 24h using transcardial perfusion fixation with 4%
paraformaldehyde. (B) Bodipy 558/568-phalloidin staining was performed on whole mounts to visualise actin (background cell staining). (C) CD-31 (CY3)
immunofluorescent labelling was performed on whole mounts to visualise the endothelium of blood vessels. Mounted samples were observed with the
LSM510 laser scanning microscope.
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upregulated in hormone refractory prostate cancer and breast
cancer (Kawai et al, 2003; Halkidou et al, 2004). Although HDAC6
activity does not drive tumour cell proliferation, HDAC6 has been
shown to regulate the response to misfolded protein stress and its
inhibition has synergistic effects with Bortezomib, which is
administered in relapsed multiple myeloma (Kawaguchi et al,
2003; Bali et al, 2005). We found potent synergy between R306465
and Bortezomib in a broad panel of haematological cell lines
indicating that activity towards HDAC6 is not essential for Histone
deacetylase inhibitors to work synergistically with Bortezomib.
Histone deacetylase 6 also promotes migration and chemotactic
movement in response to serum (Hubbert et al, 2002; Haggarty
et al, 2003). These observations have led to the suggestion that
HDAC6 may play a role in metastasis and angiogenesis. R306465,
however, was found to inhibit angiogenesis potently, presumably
through its antiproliferative effects on primary human endothelial
cells rather than effects on cell migration.
Analysis of xenograft tumours from R306465-treated mice
revealed events consistent with HDAC1 inhibition (Lagger et al,
2003). R306465 administration resulted in p21
waf1, cip1 gene
activation in both the central and peripheral tumour region,
pointing at a rapid distribution of the compound throughout the
tumour tissue. Responding cell clusters were distributed evenly
over both the peripheral and central parts of the tumour and did
not colocalise with tumour vasculature structures. A similar
homogeneous increase of H3 acetylation was observed throughout
the tumour tissue. Surprisingly, however, nearly all tumour cells
showed an increase in nuclear acetylation while the ZsGreen
expression appeared in focal spots of high fluorescence sur-
rounded by areas with weaker intensity. The cells showing ZsGreen
fluorescence also showed decreased proliferation, as assessed by
immunohistological detection of the proliferation marker PCNA,
indicating that these cells represent the responding fraction of the
tumour (data not shown). These data imply that although
increased histone acetylation may be a prerequisite for response,
it may not be sufficient to activate downstream signalling pathways
in vivo. In this regard, it is of interest that H3 acetylation has been
commonly observed in HDAC inhibitor-treated patients in the
absence of clinical response. Monitoring p21
waf1, cip1 activation
rather than the more generic histone acetylation may be a more
predictive marker of efficacy.
Summarising, our data show that R306465 not only potently
inhibits HDAC1 in vitro and in cells, but also affects HDAC1
downstream signalling pathways in vivo. The fact that HDAC1 has
been linked to regulation of cell growth and survival does not
imply per se a rationale to develop subclass-specific inhibitors.
However, the distinct biological roles of class I HDACs and
HDAC6 strongly suggest that the selectivity profile of HDAC
inhibitors may have major consequences on their clinical activity.
Evidently, to obtain single-agent antitumoral efficacy with an
HDAC inhibitor, potency towards class I HDAC family members
will be essential. Histone deacetylase 1 (but not HDAC3, HDAC6,
or HDAC8) was recently also demonstrated to be responsible for
sensitisation of cells to TRAIL-induced apoptosis (Inoue et al,
2006). R306465 represents a new HDAC inhibitor with high
selectivity towards class I HDACs capable of potently inhibiting
ovarian, lung and colon carcinoma growth in immunodeficient
mice after oral administration. These characteristics make R306465
a promising novel oral antitumoral agent with potential applic-
ability in a broad spectrum of human malignancies.
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Figure 7 R306465 inhibits tumour growth in vivo after oral administration. Nude mice were injected s.c. with A2780 ovarian, H460 lung or HCT116 colon
carcinoma cells (10
7cells per mouse) and subsequently treated p.o. with vehicle (control group, 20% HP-b-CD; K) or R306465 at either 10 (J), 20 (m)o r
40mpk (,). Mice were treated orally once daily (q.d.) between day 4 and 28 (A2780) or between day 4 and 32 (H460 and HCT116). (A) A2780 ovarian
tumours were measured at least twice a week throughout the study, and results are represented as the median tumour size, expressed in mm
3, of each
individual group (n¼10). (B) Mice were treated orally q.d. at the indicated doses. Results are represented as the treated/control values (%) of the median
tumour size (n¼10) at the end of the study.
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